Ruthenium compounds: Are they the next-era anticancer agents?

Basit Öğe Kaydı
dc.authoridVatansever, Seda/0000-0002-7415-9618
dc.authoridKavukcu, Serdar Batikan/0000-0002-1168-5012
dc.authoridturkmen, hayati/0000-0001-7411-2652
dc.authoridOzverel, Cenk Serhan/0000-0001-9932-4774
dc.contributor.authorKavukcu, Serdar Batikan
dc.contributor.authorOzverel, Cenk Serhan
dc.contributor.authorKiyak, Nadire
dc.contributor.authorVatansever, H. Seda
dc.contributor.authorTurkmen, Hayati
dc.date.accessioned2024-08-31T07:47:01Z
dc.date.available2024-08-31T07:47:01Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractThis study focuses on the cytotoxic activity of ruthenium(II) complexes, denoted as Ru1-8, which exhibit coordination with nitrogen (amine and amide), oxygen, and sulfur donor atoms, coupled with aryl and aliphatic wingtips. Specifically, the complexes were evaluated for their impact on the MCF-7 breast cancer cell line. A systematic exploration of various parameters, including solubility, donor atom type, metal number, carbon chain length, aromatic ring presence, and molecular weight, was conducted to discern their influence on cytotoxic activity. The investigation involved assessing the cell viability across five concentrations (100, 50, 25, 10, and 5 mu M) for five distinct monometallic and three bimetallic ruthenium complexes. Notably, Ru3, characterized by an extended carbon chain length (dodecyl) and favorable oil solubility facilitating cellular membrane penetration, demonstrated particularly promising results with the IC50 value of 1.03 mu M. This research underscores the critical role of ligand design in shaping the cytotoxic potential of ruthenium(II) complexes and emphasizes the suitability of the Ru(II) p-cymene complexes, as demonstrated by their robust activity against breast cancer in this specific investigation. Novel Ru(II) arene complexes were prepared. The cytotoxic activities of these complexes were investigated on MCF-7 cell line. The structure-activity relationships for the complexes containing Namine/Namine, Namine/Namide, Namide/Oamide, and Namide/Sthiolate/Sthiolate-chelating ligands were investigated. The promising results were obtained. imageen_US
dc.description.sponsorshipTurkiye Bilimsel ve Teknolojik Arastirma Kurumu [214Z098]en_US
dc.description.sponsorshipTurkiye Bilimsel ve Teknolojik Arastirma Kurumu, Grant/Award Number: 214Z098en_US
dc.identifier.doi10.1002/aoc.7363
dc.identifier.issn0268-2605
dc.identifier.issn1099-0739
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85183887648en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1002/aoc.7363
dc.identifier.urihttps://hdl.handle.net/11454/104289
dc.identifier.volume38en_US
dc.identifier.wosWOS:001152040600001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofApplied Organometallic Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectAnticancer Agentsen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectChelating Liganden_US
dc.subjectCytotoxicityen_US
dc.subjectMcf-7en_US
dc.subjectRuthenium(Ii) Arene Complexesen_US
dc.titleRuthenium compounds: Are they the next-era anticancer agents?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu